Iron deficiency anaemia revisited

Journal of Internal Medicine

Volumn 287, Issue 2, 2020, Pages 153-170

  Cappellini, M D ^a   Musallam, K M ^b   Taher, A T ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b International Network of Hematology   (United Kingdom)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

anaemia; complications; diagnosis; iron deficiency; management; pathophysiology

Indexed keywords

IRON;

CHRONIC INFLAMMATION; IRON DEFICIENCY ANEMIA; IRON HOMEOSTASIS; IRON REFRACTORY IRON DEFICIENCY ANEMIA; MALIGNANT NEOPLASM; PATHOPHYSIOLOGY; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SUPPLEMENTATION; HUMAN; RISK FACTOR;

ANEMIA, IRON-DEFICIENCY; HUMANS; IRON; RISK FACTORS;

EID: 85074971064     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.13004     Document Type: Review

References (144)

1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211–59.
2. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015; 372: 1832–43.
3. Camaschella C. New insights into iron deficiency and iron deficiency anemia. Blood Rev 2017; 31: 225–33.
4. Camaschella C. Iron deficiency. Blood 2019; 133: 30–9.
5. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet 2016; 387: 907–16.
6. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004; 53: 1190–7.
7. Kulnigg-Dabsch S, Resch M, Oberhuber G, Klinglmueller F, Gasche A, Gasche C. Iron deficiency workup reveals high incidence of autoimmune gastritis with parietal cell antibody as reliable screening test. Semin Hematol 2018; 55: 256–61.
8. Hershko C, Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood 2014; 123: 326–33.
9. Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf 2013; 4: 125–33.
10. Kiss JE, Vassallo RR. How do we manage iron deficiency after blood donation? Br J Haematol 2018; 181: 590–603.
11. Kassebaum NJ, Jasrasaria R, Naghavi M et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood 2014; 123: 615–24.
12. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010; 116: 4754–61.
13. Thomas DW, Hinchliffe RF, Briggs C et al. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol 2013; 161: 639–48.
14. Finberg KE, Heeney MM, Campagna DR et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008; 40: 569–71.
15. Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008; 8: 502–11.
16. De Falco L, Silvestri L, Kannengiesser C et al. Functional and clinical impact of novel TMPRSS6 variants in iron-refractory iron-deficiency anemia patients and genotype-phenotype studies. Hum Mutat 2014; 35: 1321–9.
17. Tsagalis G. Renal anemia: a nephrologist's view. Hippokratia 2011; 15: 39–43.
18. Macdougall IC, Bircher AJ, Eckardt KU et al. Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2016; 89: 28–39.
19. Macdougall IC. Iron supplementation in nephrology and oncology: what do we have in common? Oncologist 2011; 16(Suppl 3): 25–34.
20. Cappellini MD, Comin-Colet J, de Francisco A et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol 2017; 92: 1068–78.
21. Goodnough LT, Schrier SL. Evaluation and management of anemia in the elderly. Am J Hematol 2014; 89: 88–96.
22. Halawi R, Moukhadder H, Taher A. Anemia in the elderly: a consequence of aging? Expert Rev Hematol 2017; 10: 327–35.
23. Ferrucci L, Semba RD, Guralnik JM et al. Proinflammatory state, hepcidin, and anemia in older persons. Blood 2010; 115: 3810–6.
24. Bach V, Schruckmayer G, Sam I, Kemmler G, Stauder R. Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohort. Clin Interv Aging 2014; 9: 1187–96.
25. Aigner E, Feldman A, Datz C. Obesity as an emerging risk factor for iron deficiency. Nutrients 2014; 6: 3587–600.
26. Zarshenas N, Nacher M, Loi KW, Jorgensen JO. Investigating nutritional deficiencies in a group of patients 3 years post laparoscopic sleeve gastrectomy. Obes Surg 2016; 26: 2936–43.
27. Cepeda-Lopez AC, Allende-Labastida J, Melse-Boonstra A et al. The effects of fat loss after bariatric surgery on inflammation, serum hepcidin, and iron absorption: a prospective 6-mo iron stable isotope study. Am J Clin Nutr 2016; 104: 1030–8.
28. Steenackers N, Van der Schueren B, Mertens A et al. Iron deficiency after bariatric surgery: what is the real problem? Proc Nutr Soc 2018; 77: 445–55.
29. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013; 34: 816–29.
30. McDonagh T, Macdougall IC. Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? Eur J Heart Fail 2015; 17: 248–62.
31. Jankowska EA, Malyszko J, Ardehali H et al. Iron status in patients with chronic heart failure. Eur Heart J 2013; 34: 827–34.
32. Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem J 2011; 434: 365–81.
33. Theurl I, Hilgendorf I, Nairz M et al. On-demand erythrocyte disposal and iron recycling requires transient macrophages in the liver. Nat Med 2016; 22: 945–51.
34. Corna G, Caserta I, Monno A et al. The repair of skeletal muscle requires iron recycling through macrophage ferroportin. J Immunol 2016; 197: 1914–25.
35. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090–3.
36. Zhang AS, Anderson SA, Wang J et al. Suppression of hepatic hepcidin expression in response to acute iron deprivation is associated with an increase of matriptase-2 protein. Blood 2011; 117: 1687–99.
37. Pasricha SR, Lim PJ, Duarte TL et al. Hepcidin is regulated by promoter-associated histone acetylation and HDAC3. Nat Commun 2017; 8: 403.
38. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014; 46: 678–84.
39. Mastrogiannaki M, Matak P, Peyssonnaux C. The gut in iron homeostasis: role of HIF-2 under normal and pathological conditions. Blood 2013; 122: 885–92.
40. Zhang DL, Wu J, Shah BN et al. Erythrocytic ferroportin reduces intracellular iron accumulation, hemolysis, and malaria risk. Science 2018; 359: 1520–3.
41. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011–23.
42. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood 2019; 133: 40–50.
43. Guida C, Altamura S, Klein FA et al. A novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia. Blood 2015; 125: 2265–75.
44. Stoffel NU, Lazrak M, Bellitir S et al. The opposing effects of acute inflammation and iron deficiency anemia on serum hepcidin and iron absorption in young women. Haematologica 2019; 104: 1143–9.
45. GHO. Global Health Observatory data repository 2016. Available at: http://apps.who.int/gho/data/node.home.
46. Fraser IS, Mansour D, Breymann C, Hoffman C, Mezzacasa A, Petraglia F. Prevalence of heavy menstrual bleeding and experiences of affected women in a European patient survey. Int J Gynaecol Obstet 2015; 128: 196–200.
47. Stauder R, Valent P, Theurl I. Anemia at older age: etiologies, clinical implications, and management. Blood 2018; 131: 505–14.
48. Cable RG, Glynn SA, Kiss JE et al. Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion 2011; 51: 511–22.
49. Jankowska EA, Rozentryt P, Witkowska A et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31: 1872–80.
50. Cohen-Solal A, Damy T, Terbah M et al. High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail 2014; 16: 984–91.
51. Klip IT, Comin-Colet J, Voors AA et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013; 165: 575–582.e3.
52. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 2011; 58: 1241–51.
53. Yeo TJ, Yeo PS, Ching-Chiew Wong R et al. Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. Eur J Heart Fail 2014; 16: 1125–32.
54. Peyrin-Biroulet L, Williet N, Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr 2015; 102: 1585–94.
55. McClellan W, Aronoff SL, Bolton WK et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20: 1501–10.
56. Ludwig H, Muldur E, Endler G, Hubl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 2013; 24: 1886–92.
57. Munoz M, Laso-Morales MJ, Gomez-Ramirez S, Cadellas M, Nunez-Matas MJ, Garcia-Erce JA. Pre-operative haemoglobin levels and iron status in a large multicentre cohort of patients undergoing major elective surgery. Anaesthesia 2017; 72: 826–34.
58. Musallam KM, Tamim HM, Richards T et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet 2011; 378: 1396–407.
59. Munoz M, Acheson AG, Auerbach M et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia 2017; 72: 233–47.
60. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol 2016; 91: 31–8.
61. Steiber A, Leon JB, Secker D et al. Multicenter study of the validity and reliability of subjective global assessment in the hemodialysis population. J Ren Nutr 2007; 17: 336–42.
62. Falkingham M, Abdelhamid A, Curtis P, Fairweather-Tait S, Dye L, Hooper L. The effects of oral iron supplementation on cognition in older children and adults: a systematic review and meta-analysis. Nutr J 2010; 9: 4.
63. Andro M, Le Squere P, Estivin S, Gentric A. Anaemia and cognitive performances in the elderly: a systematic review. Eur J Neurol 2013; 20: 1234–40.
64. Tt Brownlie, Utermohlen V, Hinton PS, Giordano C, Haas JD. Marginal iron deficiency without anemia impairs aerobic adaptation among previously untrained women. Am J Clin Nutr 2002; 75: 734–42.
65. Haas JD, Brownlie T. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 2001; 131: 676S–88S; discussion 88S–90S.
66. Wang W, Bourgeois T, Klima J, Berlan ED, Fischer AN, O'Brien SH. Iron deficiency and fatigue in adolescent females with heavy menstrual bleeding. Haemophilia 2013; 19: 225–30.
67. Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet 1996; 348: 992–6.
68. Musallam KM, Taher AT. Iron deficiency beyond erythropoiesis: should we be concerned? Curr Med Res Opin 2018; 34: 81–93.
69. Mirza FG, Abdul-Kadir R, Breymann C, Fraser IS, Taher A. Impact and management of iron deficiency and iron deficiency anemia in women's health. Expert Rev Hematol 2018; 11: 727–36.
70. Cooke AG, McCavit TL, Buchanan GR, Powers JM. Iron deficiency anemia in adolescents who present with heavy menstrual bleeding. J Pediatr Adolesc Gynecol 2017; 30: 247–50.
71. Achebe MM, Gafter-Gvili A. How I treat anemia in pregnancy: iron, cobalamin, and folate. Blood 2017; 129: 940–9.
72. Cantwell R, Clutton-Brock T, Cooper G et al. Saving mothers' lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011; 118(Suppl 1): 1–203.
73. Colomer J, Colomer C, Gutierrez D et al. Anaemia during pregnancy as a risk factor for infant iron deficiency: report from the Valencia Infant Anaemia Cohort (VIAC) study. Paediatr Perinat Epidemiol 1990; 4: 196–204.
74. Congdon EL, Westerlund A, Algarin CR et al. Iron deficiency in infancy is associated with altered neural correlates of recognition memory at 10 years. J Pediatr 2012; 160: 1027–33.
75. Culleton BF, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Hemmelgarn BR. Impact of anemia on hospitalization and mortality in older adults. Blood 2006; 107: 3841–6.
76. Cleland JG, Zhang J, Pellicori P et al. Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure. JAMA Cardiol 2016; 1: 539–47.
77. Anker SD, Comin Colet J, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436–48.
78. Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur J Heart Fail 2012; 14: 423–9.
79. Jankowska EA, Rozentryt P, Witkowska A et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail 2011; 17: 899–906.
80. Enjuanes C, Bruguera J, Grau M et al. Iron status in chronic heart failure: impact on symptoms, functional class and submaximal exercise capacity. Rev Esp Cardiol (Engl Ed) 2016; 69: 247–55.
81. Enjuanes C, Klip IT, Bruguera J et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol 2014; 174: 268–75.
82. Xu W, Barrientos T, Mao L, Rockman HA, Sauve AA, Andrews NC. Lethal cardiomyopathy in mice lacking transferrin receptor in the heart. Cell Rep 2015; 13: 533–45.
83. Dowling TC. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. Am J Health Syst Pharm 2007; 64: S3–7; quiz S23-5.
84. Finkelstein FO, Story K, Firanek C et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 33–8.
85. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006; 69: 560–4.
86. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659–63.
87. Thorp ML, Johnson ES, Yang X, Petrik AF, Platt R, Smith DH. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology 2009; 14: 240–6.
88. Danese S, Hoffman C, Vel S et al. Anaemia from a patient perspective in inflammatory bowel disease: results from the European Federation of Crohn's and Ulcerative Colitis Association's online survey. Eur J Gastroenterol Hepatol 2014; 26: 1385–91.
89. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006; 12: 123–30.
90. Fowler AJ, Ahmad T, Phull MK, Allard S, Gillies MA, Pearse RM. Meta-analysis of the association between preoperative anaemia and mortality after surgery. Br J Surg 2015; 102: 1314–24.
91. Ferraris VA, Davenport DL, Saha SP, Austin PC, Zwischenberger JB. Surgical outcomes and transfusion of minimal amounts of blood in the operating room. Arch Surg 2012; 147: 49–55.
92. Munoz M, Acheson AG, Bisbe E et al. An international consensus statement on the management of postoperative anaemia after major surgical procedures. Anaesthesia 2018; 73: 1418–31.
93. Kemper AR, Fan T, Grossman DC, Phipps MG. Gaps in evidence regarding iron deficiency anemia in pregnant women and young children: summary of US Preventive Services Task Force recommendations. Am J Clin Nutr 1555S; 106: 1555S–8S.
94. Pasricha SR. Should we screen for iron deficiency anaemia? A review of the evidence and recent recommendations. Pathology 2012; 44: 139–47.
95. Breymann C, Honegger C, Hosli I, Surbek D. Diagnosis and treatment of iron-deficiency anaemia in pregnancy and postpartum. Arch Gynecol Obstet 2017; 296: 1229–34.
96. Juul SE, Derman RJ, Auerbach M. Perinatal iron deficiency: implications for mothers and infants. Neonatology 2019; 115: 269–74.
97. WHO. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Vitamin and Mineral Nutrition Information System. Geneva: World Health Organization, 2011.
98. Centers for Disease Control and Prevention. Recommendations to prevent and control iron deficiency in the United States. MMWR Recomm Rep 1998; 47: 1–29.
99. Garcia-Casal MN, Pasricha SR, Sharma AJ, Pena-Rosas JP. Use and interpretation of hemoglobin concentrations for assessing anemia status in individuals and populations: results from a WHO technical meeting. Ann N Y Acad Sci 2019; 1450: 5–14.
100. Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem 1998; 44: 45–51.
101. Garcia-Casal MN, Pena-Rosas JP, Pasricha SR. Rethinking ferritin cutoffs for iron deficiency and overload. Lancet Haematol 2014; 1: e92–4.
102. Namaste SM, Rohner F, Huang J et al. Adjusting ferritin concentrations for inflammation: Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project. Am J Clin Nutr 2017; 106: 359S–71S.
103. Infusino I, Braga F, Dolci A, Panteghini M. Soluble transferrin receptor (sTfR) and sTfR/log ferritin index for the diagnosis of iron-deficiency anemia. A meta-analysis. Am J Clin Pathol 2012; 138: 642–9.
104. Bregman DB, Morris D, Koch TA, He A, Goodnough LT. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 2013; 88: 97–101.
105. Prentice AM, Doherty CP, Abrams SA et al. Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children. Blood 2012; 119: 1922–8.
106. van der Vorm LN, Hendriks JC, Laarakkers CM et al. Toward worldwide hepcidin assay harmonization: identification of a commutable secondary reference material. Clin Chem 2016; 62: 993–1001.
107. World Health Organization. Guideline: Fortification of Rice with Vitamins and Minerals as a Public Health Strategy. Geneva: World Health Organization, 2018.
108. World Health Organization. WHO Guideline: Fortification of Maize Flour and Corn Meal with Vitamins and Minerals. Geneva: World Health Organization, 2016.
109. World Health Organization. Guideline: Daily Iron Supplementation in Infants and Children. Geneva: World Health Organization, 2016.
110. Neuberger A, Okebe J, Yahav D, Paul M. Oral iron supplements for children in malaria-endemic areas. Cochrane Database Syst Rev 2016; 2: CD006589.
111. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071–84.
112. World Health Organization. Guideline: Daily Iron Supplementation in Adult Women and Adolescent Girls. Geneva: World Health Organization, 2016.
113. Hudak L, Jaraisy A, Haj S, Muhsen K. An updated systematic review and meta-analysis on the association between Helicobacter pylori infection and iron deficiency anemia. Helicobacter 2017; 22: e12330.
114. Moretti D, Goede JS, Zeder C et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood 2015; 126: 1981–9.
115. Stoffel NU, Cercamondi CI, Brittenham G et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol 2017; 4: e524–e33.
116. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011; 3: 12–33.
117. Auerbach M, Macdougall I. The available intravenous iron formulations: History, efficacy, and toxicology. Hemodial Int 2017; 21(Suppl 1): S83–S92.
118. Bencaiova G, von Mandach U, Zimmermann R. Iron prophylaxis in pregnancy: intravenous route versus oral route. Eur J Obstet Gynecol Reprod Biol 2009; 144: 135–9.
119. Breymann C, Milman N, Mezzacasa A, Bernard R, Dudenhausen J. investigators F-A. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). J Perinat Med 2017; 45: 443–53.
120. Mahey R, Kriplani A, Mogili KD, Bhatla N, Kachhawa G, Saxena R. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. Int J Gynaecol Obstet 2016; 133: 43–8.
121. Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trial. Vox Sang 2017; 112: 219–28.
122. Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Single-dose intravenous iron infusion versus red blood cell transfusion for the treatment of severe postpartum anaemia: a randomized controlled pilot study. Vox Sang 2017; 112: 122–31.
123. Lewis GD, Malhotra R, Hernandez AF et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA 2017; 317: 1958–66.
124. Filippatos G, Farmakis D, Colet JC et al. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail 2013; 15: 1267–76.
125. Ponikowski P, van Veldhuisen DJ, Comin-Colet J et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J 2015; 36: 657–68.
126. Jankowska EA, Tkaczyszyn M, Suchocki T et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail 2016; 18: 786–95.
127. Grote Beverborg N, Klip IT, Meijers WC et al. Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients. Circ Heart Fail 2018; 11: e004519.
128. Lee T, Clavel T, Smirnov K et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut 2017; 66: 863–71.
129. van Rheenen PF, Aloi M, Biron IA et al. European Crohn's and Colitis Organisation topical review on transitional care in inflammatory bowel disease. J Crohns Colitis 2017; 11: 1032–8.
130. Ott C, Liebold A, Takses A, Strauch UG, Obermeier F. High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort. Gastroenterol Res Pract 2012; 2012: 595970.
131. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011; 26: 1599–607.
132. Macdougall IC, White C, Anker SD et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 2019; 380: 447–58.
133. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019–32.
134. Salim SA, Cheungpasitporn W, Elmaraezy A et al. Infectious complications and mortality associated with the use of IV iron therapy: a systematic review and meta-analysis. Int Urol Nephrol 2019; 51: 1855–65.
135. Lebrun F, Klastersky J, Levacq D, Wissam Y, Paesmans M. Intravenous iron therapy for anemic cancer patients: a review of recently published clinical studies. Support Care Cancer 2017; 25: 2313–9.
136. Ludwig H, Evstatiev R, Kornek G et al. Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr 2015; 127: 907–19.
137. Naoum FA. Iron deficiency in cancer patients. Rev Bras Hematol Hemoter 2016; 38: 325–30.
138. Meybohm P, Froessler B, Goodnough LT et al. "Simplified international recommendations for the implementation of patient blood management" (SIR4PBM). Perioper Med (Lond) 2017; 6: 5.
139. Keeler BD, Simpson JA, Ng O et al. Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer. Br J Surg 2017; 104: 214–21.
140. Froessler B, Palm P, Weber I, Hodyl NA, Singh R, Murphy EM. The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial. Ann Surg 2016; 264: 41–6.
141. Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (Monofer(R)) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang 2015; 109: 257–66.
142. Calleja JL, Delgado S, del Val A et al. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. Int J Colorectal Dis 2016; 31: 543–51.
143. Khalafallah AA, Yan C, Al-Badri R et al. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. Lancet Haematol 2016; 3: e415–25.
144. Kim YW, Bae JM, Park YK et al. Effect of intravenous ferric carboxymaltose on hemoglobin response among patients with acute isovolemic anemia following gastrectomy: the FAIRY randomized clinical trial. JAMA 2017; 317: 2097–104.